Dual amylin and calcitonin receptor agonists (DACRAs) are a class of drugs that act as agonists at the amylin receptor and calcitonin receptor that are under development as therapies for obesity and type 2 diabetes.
Examples are cagrilintide, Petrelintide, ACCG-2671 and the KBP family derived from salmon calcitonin,[1] including KBP‐042,[2] KBP-066A,[3] KBP-089,[4] and KBP-336.
[5]
This pharmacology-related article is a stub.
You can help Wikipedia by expanding it.